At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 148 enrolled
Drug / intervention
DE-111 ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term Open-label Study of DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension -Phase 3-
In Brief
A Phase 3 clinical trial evaluating DE-111 ophthalmic solution for Open Angle Glaucoma or Ocular Hypertension. Completed, enrolled 148 participants across 1 site.
Detailed Summary
Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartMay 2011
Primary CompletionMar 2013
TodayJul 2026
First PostedApr 27, 2011
Enrollment StartMay 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.2 years ago
Interventions
DE-111 ophthalmic solutiondrug